NDAINTRAVENOUSSOLUTION
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CORPHEDRA (ephedrine sulfate) by Pfizer is α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. First approved in 2017.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORPHEDRA (ephedrine sulfate) is an intravenous sympathomimetic amine that activates α- and β-adrenergic receptors while indirectly releasing norepinephrine from sympathetic neurons. It is used to treat hypotension by increasing arterial pressure, cardiac output, and peripheral resistance. The drug is indicated for patients requiring acute hemodynamic support in acute care settings.
Peak
Product is at peak revenue stage with moderate competitive pressure (30); stable to mature portfolio position suggests focus on market maintenance and defensive strategies.
Mechanism of Action
α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Started Apr 2006
34 enrolled
Healthy
Career Relevance
CORPHEDRA represents a peak-stage acute care injectable with stable market position but zero linked job postings, reflecting a mature portfolio product with smaller dedicated teams. Career roles focus on protecting market share, health system relationships, and formulary positioning in a competitive vasopressor landscape rather than growth or launch activities.
Brand Manager
Worked on CORPHEDRA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.